Oulman Roxanne sold 13,989 shares of Klaviyo, Inc. at $20.36 for −$285k on Nov 6, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Director
DIR
Filed Nov 9, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$284,816.04Shares × reported price
Shares traded
13,989Series A Common Stock
Price per share
$20.36Reported price. Read footnotes for ranges.
% of reported position traded
37.46%This security and ownership context
Holdings after
23,354Direct
Trade date
Nov 6, 2026Sell
Filed
Nov 9, 2026, 4:29 PM ET3-day reporting delay
Accession
0001470831-26-000988Code S · Transaction 395944
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 37,343 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

KVYO price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
KVYO · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 16, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −16%1w ago −2.8%1d ago +0.5%
Returns since7d30d90d180d1y

Footnotes in full

F1: Reflects the transfer of 12,881 shares of Series A Common Stock, par value $0.001 per share ("Series A Common Stock") from the Roxanne Oulman 2025 GRAT to The Grant Oulman & Roxanne Oulman Revocable Living Trust, of which the Reporting Person serves as a co-trustee, in accordance with the exemption afforded by Rule 16a-13 of the Securities Exchange Act of 1934, as amended. Following the transfer, 12,881 shares of Series A Common Stock are held by The Grant Oulman & Roxanne Oulman Revocable Living Trust and 3,894 shares of Series A Common Stock are held by the Roxanne Oulman 2025 GRAT. F2: Shares held by The Grant Oulman & Roxanne Oulman Revocable Living Trust, of which the Reporting Person serves as a co-trustee. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose. F3: Shares held by the Roxanne Oulman 2025 GRAT, of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose. F4: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.32 to $20.40 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F6: Consists of (i) 8,532 shares of the Issuer's Series A Common Stock, and (ii) 14,822 unvested restricted stock units awarded under the Issuer's 2023 Stock Option and Incentive Plan, each representing the contingent right to receive one share of Series A Common Stock upon vesting and settlement.